A Systematic Review of Strategies to Prevent Cisplatin‐Induced Nephrotoxicity
Daniel J. Crona,Aimee Faso,Tomohiro F. Nishijima,Kathleen A. McGraw,Matthew D. Galsky,Matthew I. Milowsky +5 more
TLDR
It is shown that hydration is essential for all patients to prevent cisplatin-induced nephrotoxicity, and short-duration, low-volume, outpatient hydration regimens appear to be safe and feasible, even in patients receiving intermediate- to high-dose cisPlatin.Abstract:
Introduction Cisplatin, a platinum-based antineoplastic agent, is the cornerstone for the treatment of many malignancies. Nephrotoxicity is the primary dose-limiting toxicity, and various hydration regimens and supplementation strategies are used to prevent cisplatin-induced kidney injury. However, evidence-based recommendations on specific hydration regimens are limited. A systematic review was performed to evaluate clinical studies that have examined hydration and supplementation strategies to prevent cisplatin-induced nephrotoxicity. Materials and methods PubMed and Excerpta Medica databases were searched from 1966 through October 2015 for clinical trials and other studies focused on hydration regimens to prevent nephrotoxicity in cancer patients treated with cisplatin. The University of Oxford Centre for Evidence-Based Medicine criteria were used to grade level of evidence. Results Among the 1,407 identified studies, 24 were included in this systematic review. All studies differed on type, volume, and duration of hydration. Among the 24 studies, 5 evaluated short-duration hydration, 4 evaluated low-volume hydration, 4 investigated magnesium supplementation, and 7 reviewed forced diuresis with hydration. Short-duration and lower-volume hydration regimens are effective in preventing cisplatin-induced nephrotoxicity. Magnesium supplementation may have a role as a nephroprotectant, and forced diuresis may be appropriate in some patients receiving cisplatin. Conclusion Hydration is essential for all patients to prevent cisplatin-induced nephrotoxicity. Specifically, short-duration, low-volume, outpatient hydration with magnesium supplementation and mannitol forced diuresis (in select patients) represent best practice principles for the safe use of cisplatin. The Oncologist 2017;22:609-619 IMPLICATIONS FOR PRACTICE: The findings contained within this systematic review show that (a) hydration is essential for all patients to prevent cisplatin-induced nephrotoxicity, (b) short-duration, low-volume, outpatient hydration regimens appear to be safe and feasible, even in patients receiving intermediate- to high-dose cisplatin, (c) magnesium supplementation (8-16 milliequivalents) may limit cisplatin-induced nephrotoxicity, and (d) mannitol may be considered for high-dose cisplatin and/or patients with preexisting hypertension. These findings have broad implications for clinical practice and represent best practice principles for the prevention of cisplatin-induced nephrotoxicity.read more
Citations
More filters
Journal ArticleDOI
The rediscovery of platinum-based cancer therapy
TL;DR: New findings related to sensitivity and resistance to these drugs as well as recent advances in platinum drug development are discussed, including genome-wide functional screening approaches have revealed interesting insights into Pt drug uptake.
Journal ArticleDOI
Molecular mechanisms of cisplatin-induced nephrotoxicity: a balance on the knife edge between renoprotection and tumor toxicity.
Vladislav Volarevic,Bojana Djokovic,Marina Gazdic Jankovic,C. Randall Harrell,Crissy Fellabaum,Valentin Djonov,Nebojsa Arsenijevic +6 more
TL;DR: This review article describes in detail signaling pathways involved in CDDP-induced apoptosis of renal tubular cells, oxidative stress and inflammatory response in injured kidneys in order to pave the way for the design of new therapeutic approaches that can minimize CD DP-induced nephrotoxicity.
Journal ArticleDOI
Myricetin: A review of the most recent research.
Xiaominting Song,Lu Tan,Miao Wang,Chaoxiang Ren,Chuanjie Guo,Bo Yang,Yali Ren,Zhixing Cao,Yuzhi Li,Jin Pei +9 more
TL;DR: Theoretical basis for the clinical application of MYR is provided and a reference for its further use, and the potential molecular mechanisms of its effects are discussed.
Journal ArticleDOI
Cisplatin-Induced Rodent Model of Kidney Injury: Characteristics and Challenges.
TL;DR: The present paper is aimed at giving a concise insight into the complex characteristics of cisplatin rodent model and heterogeneity of cisPlatin dosage regimens as well as outlining factors that can severely influence the outcome of the model and the study.
Journal ArticleDOI
Natural products: potential treatments for cisplatin-induced nephrotoxicity.
Chunyan Fang,Da-Yong Lou,Li-Qin Zhou,Jincheng Wang,Bo Yang,Qiaojun He,Jiajia Wang,Qinjie Weng +7 more
TL;DR: In this paper, the authors describe the molecular mechanisms of cisplatin-induced nephrotoxicity and summarize recent findings in the field of natural products that undermine these mechanisms to protect against kidney damage and provide potential strategies for AKI treatment.
References
More filters
Journal ArticleDOI
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
TL;DR: Moher et al. as mentioned in this paper introduce PRISMA, an update of the QUOROM guidelines for reporting systematic reviews and meta-analyses, which is used in this paper.
Journal Article
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement [in Spanish]
David Moher,Alessandro Liberati,Jennifer Tetzlaff,Douglas G. Altman,Gerd Antes,David C. Atkins,Virginia Barbour,N Barrowman,Jesse A. Berlin,J Clark,Mike Clarke,Deborah J. Cook,Roberto D'Amico,Jonathan J Deeks,Philip J. Devereaux,Kay Dickersin,M Egger,E Ernst,P C Gøtzsche,Jeremy M. Grimshaw,G Guyatt,Julian P T Higgins,Ioannidis Jpa.,Jos Kleijnen,Tom Lang,N Magrini,D McNamee,Lorenzo Moja,C Mulrow,M Napoli,Andrew D Oxman,B Pham,Drummond Rennie,Margaret Sampson,Kenneth F. Schulz,Paul G. Shekelle,David Tovey,Peter Tugwell +37 more
Journal ArticleDOI
Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.
TL;DR: A 2-day consensus conference on acute renal failure (ARF) in critically ill patients was organized by ADQI as discussed by the authors, where the authors sought to review the available evidence, make recommendations and delineate key questions for future studies.
Journal ArticleDOI
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Navjotsingh Pabla,Zheng Dong +1 more
TL;DR: Examination of tumor-bearing animals and identification of novel renoprotective strategies that do not diminish the anticancer efficacy of cisplatin are essential to the development of clinically applicable interventions.
Related Papers (5)
Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Navjotsingh Pabla,Zheng Dong +1 more